BiotechTube

I-020502

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Burns

Conditions

Burns

Trial Timeline

Apr 1, 2007 → Jan 1, 2009

NCT ID
NCT00471939

About I-020502

I-020502 is a phase 2 stage product being developed by Baxter for Burns. The current trial status is completed. This product is registered under clinical trial identifier NCT00471939. Target conditions include Burns.

What happened to similar drugs?

3 of 6 similar drugs in Burns were approved

Approved (3) Terminated (3) Active (3)
✅Ceftolozane/tazobactamMerckApproved
✅Sulfamylon® For 5 % Topical Solution + Topical Antimicrobial/Antifungal MedicationsViatrisApproved
✅Pathogen-Reduced Plasma + Crystalloid SolutionsCerusApproved
🔄Ciprofloxacin (BAYO9867) + Ciprofloxacin (BAYO9867)BayerPhase 3
🔄NexoBrid + Gel VehicleMediWoundPhase 3
🔄NexoBridMediWoundPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00471939Phase 2Completed

Competing Products

12 competing products in Burns

See all competitors
ProductCompanyStageHype Score
R-Pdf/Gbb 0.01% gelJohnson & JohnsonPhase 2
31
Ceftolozane/tazobactamMerckApproved
35
linezolidPfizerPhase 1
29
Somatropin + 0.09% Saline SolutionPfizerPhase 2/3
38
Ciprofloxacin (BAYO9867) + Ciprofloxacin (BAYO9867)BayerPhase 3
37
cP12United TherapeuticsPhase 2
39
cNP8United TherapeuticsPhase 1
26
Sulfamylon® For 5 % Topical Solution + Topical Antimicrobial/Antifungal MedicationsViatrisApproved
32
Sheet skin grafts affixed with Fibrin Sealant (lyophilized) with 4 IU/mL ThrombinBaxterPhase 1/2
29
Pathogen-Reduced Plasma + Crystalloid SolutionsCerusApproved
25
NexoBrid + Gel VehicleMediWoundPhase 3
30
NexoBridMediWoundPhase 3
30